GLPG

Galapagos NV - ADR

Healthcare


Presented:06/16/2020
Price:$201.64
Cap:$13.16B
Current Price:$29.34
Cap:$1.93B

Presented

Date06/16/2020
Price$201.64
Market Cap$13.16B
Ent Value$6.91B
P/E Ratio67.15x
Book Value$49.92
Div Yield0%
Shares O/S65.25M
Ave Daily Vol138,774
Short IntN/A

Current

Price$29.34
Market Cap$1.93B
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research & Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Publicly traded companies mentioned herein: Galapagos NV (GLPG)Gilead Sciences Inc (GILD)

Highlights

The presenter is short shares of Galapagos (GLPG). Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren’s syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. GLPG struck a partnership with Gilead (GILD) for the development and commercialization of filgotinib, as well as other pipeline molecules; however, he is concerned that there may be some issues with the dosing, data, or other delays that could weigh on the stock price over the remainder of 2020. 

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.